Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced financial results for the quarter ended March 31, 2013.
For the quarter ended March 31, 2013, the Company incurred a net loss of $5.0 million, or $0.10 per basic and diluted share compared to a net loss of $7.9 million for the quarter ended March 31, 2012, or $0.21 per basic and diluted share.
Help employers find you! Check out all the jobs and post your resume.
